Robert Prins, PhD
Dr. Robert Prins' research group studies immune-based therapies for the treatment of malignant glioma. Despite recent advances in traditional treatment options, the prognosis for these patients has not changed appreciably in twenty years. Thus, these patients are left with few treatment options. Members of Prins' research group are attempting to apply what they learn from pre-clinical models towards the implementation of immunotherapy clinical trials for brain tumor patients. This work is truly ÒtranslationalÓ in nature and straddles the boundary between clinical medicine and basic research. On one hand, Prins' group spends a significant amount of time trying to understand the mechanisms by which tumor-specific T-cells can be activated to target tumor cells in the brain. On the other hand, Prins leads the laboratory effort for immunotherapy clinical trials at UCLA in glioma patients; in this aspect, he generates dendritic cell vaccines for these patients. This work represents the Òbench to bedsideÓ philosophy and truly is an active synergy between laboratory and clinical medicine.
Antonios JP, Soto H, Everson RG, Moughon D, Orpilla JR, Shin NP, Sedighim S, Treger J, Odesa S, Tucker A, Yong WH, Li G, Cloughesy TF, Liau LM, Prins RM. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma. Neuro Oncol. 2017 Jun 1;19(6):796-807. doi: 10.1093/neuonc/now287.
Antonios JP, Soto H, Everson RG, Orpilla J, Moughon D, Shin N, Sedighim S, Yong WH, Li G, Cloughesy TF, Liau LM, Prins RM. PD-1 blockade enhances the vaccination-induced immune response in glioma. JCI Insight. 2016 Jul 7;1(10). pii: e87059.
Hsu M, Sedighim S, Wang T, Antonios JP, Everson RG, Tucker AM, Du L, Emerson R, Yusko E, Sanders C, Robins HS, Yong WH, Davidson TB, Li G, Liau LM, Prins RM. TCR Sequencing Can Identify and Track Glioma-Infiltrating T Cells after DC Vaccination. Cancer Immunol Res. 2016 May;4(5):412-418. doi: 10.1158/2326-6066.CIR-15-0240. Epub 2016 Mar 11.
Okada H, Weller M, Huang R, Finocchiaro G, Gilbert MR, Wick W, Ellingson BM, Hashimoto N, Pollack IF, Brandes AA, Franceschi E, Herold-Mende C, Nayak L, Panigrahy A, Pope WB, Prins R, Sampson JH, Wen PY, Reardon DA. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 2015 Nov;16(15):e534-42. doi: 10.1016/S1470-2045(15)00088-1. Review.
Everson RG, Antonios JP, Lisiero DN, Soto H, Scharnweber R, Garrett MC, Yong WH, Li N, Li G, Kruse CA, Liau LM, Prins RM. Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma. Neuro Oncol. 2016 Mar;18(3):368-78. doi: 10.1093/neuonc/nov153. Epub 2015 Sep 1.